Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01941550
Other study ID # 13-005
Secondary ID
Status Terminated
Phase Phase 2
First received July 22, 2013
Last updated September 12, 2016
Start date July 2013
Est. completion date January 2016

Study information

Verified date September 2016
Source RWTH Aachen University
Contact n/a
Is FDA regulated No
Health authority Germany: Ministry of Work, Health and Social Affairs in North Rhine-Westph
Study type Interventional

Clinical Trial Summary

This study is aimed at evaluating the efficacy regarding the response rate and metastasis-free survival time of cabazitaxel as a neoadjuvant treatment in patients with high risk prostate cancer.


Description:

Patients will be treated by 6 cycles of Cabazitaxel 25 mg/m2 every three weeks and extended radical prostatectomy and extended pelvic lymphadenectomy 4 weeks after completion of chemotherapy. Multiparametric MRI will be performed at baseline, after 3 cycles and after 6 cycles. If there will be evidence of clinical progression after 3rd cycle, patients can be removed from the study and given local therapy, including radical prostatectomy or external beam radiotherapy, at the discretion of the patient's physicians. If patients have evidence of response, they continue on treatment for a total of 6 cycles. If multiparametric MRI demonstrates stable disease an individual risk-benefit analysis has to be performed with regard to continuing or to stopping the neoadjuvant treatment since the definition stable disease includes patients with ≤ 20% tumour shrinkage or tumour progression


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Surgically resectable high risk prostate cancer with a 5-year relapse probability = 60% according to the Kattan pre-operative nomogram (cancer 2009, 115: 1005-1010)

- no prior therapy for prostate cancer such as androgen deprivation therapy, radiation therapy, or chemotherapy

- ECOG performance status 0-1

- No evidence of active infection

- Hemoglobin >9.0 g/dL

- Absolute neutrophil count >1.5 x 109/L,

- Platelet count >100 x 109/L,

- AST/SGOT and/or ALT/SGPT <2.5 x ULN;

- Total bilirubin <1.0 x ULN,

- Serum creatinine <1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance <60 mL/min should be excluded)

- Patient information and signature of informed consent

- Male = 18 years

- Patients of reproductive age must take appropriate contraceptive precautions during and for 6 months after the end of their participation in the study

Exclusion Criteria:

- Evidence of lymph node, visceral or bone metastases

- previous major intrapelvic surgery

- previous radiation therapy to the small pelvis

- any type of malignancies within the last 5 years except basalioma and non-muscle invasive urothelial cancer of the urinary bladder

- previous chemotherapy with taxanes (docetaxel, paclitaxel, cabazitaxel) for any indication

- Hypersensitivity to the active substance or to any of the excipients

- Known or suspected brain metastases or leptomeningeal metastases

- Active or symptomatic viral hepatitis or chronic liver disease

- Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Cabazitaxel chemotherapy
given in 6 cycles

Locations

Country Name City State
Germany Uniklinik RWTH Aachen Aachen Nordrhein-Westfalen

Sponsors (1)

Lead Sponsor Collaborator
RWTH Aachen University

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete pathological response rate Primary endpoint: overall or cancer specific survival nor progression-free survival(PFS) in 5 years. Composite measurement.
Key-parameters:
Complete pathohistological remission
Intra/perioperative compl.
PFS
Metastasis-FS
Biochemical, radiological, clinical PFS and androgen-deprivation FS
Objective progr. during cabazitaxel therapy (cab.th.) and post surgery
PSA response at the end of cab.th.
PSA progression after 12 w. of cab.th.
Percentage of pat. with undetectable PSA (<0.1 ng/ml) post surgery
Relationship between PSA kinetics, histol. response and MRI response
Role of pathohistol. parameters such as intraductal, cribriform growth patterns and effect on response
Immunohistochemical evaluation of prostate biopsy and radical prostatectomy specimens of markers potentially associated with chemoresistance: growth differentiation factor 15, surviving, beta-tubuline I & II, p53, bcl-2,
Measurement of the serum concentrations of free circulating mDNA
5 years No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06041490 - Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation Phase 2
Recruiting NCT03978663 - Three Fraction Radiation to Induce Immuno-Oncologic Response N/A
Withdrawn NCT05120622 - Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT05254899 - Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL Phase 2
Recruiting NCT04947098 - Prevent Cancer- Greenville
Recruiting NCT06020443 - Adherence to Lung Cancer Screening by Low-dose Thoracic CT in Haut-Rhin Department, France. N/A
Completed NCT02308280 - Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients Phase 2
Active, not recruiting NCT06046625 - Needs and Preferences of Patients With Head-neck Cutaneous SCC
Recruiting NCT06277050 - Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma Phase 3
Completed NCT03343249 - Adjunctive Smart Phone Based Smoking Cessation Treatment N/A
Recruiting NCT06327568 - Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens
Recruiting NCT04334993 - Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study Phase 2
Recruiting NCT05482880 - Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
Recruiting NCT05498272 - Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations Phase 2
Terminated NCT01479192 - Fenretinide in Healthy Young Women at Genetic and Familial Risk Phase 3
Recruiting NCT05557487 - Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration
Recruiting NCT04217356 - Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
Recruiting NCT04740866 - Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer N/A
Recruiting NCT04905329 - A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
Active, not recruiting NCT01827137 - WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation N/A